Introduction
Absci Corporation is a clinical-stage biotechnology company headquartered in Vancouver, Washington — in the United States, not Canada — that designs breakthrough therapeutics using generative artificial intelligence. Sean McClain founded Absci in 2011 and serves as Founder and Chief Executive Officer, a role confirmed in investor relations news releases reviewed in July 2026, including the May 13, 2025 announcement of first participants dosed in a Phase 1 trial of ABS-101, an AI-designed anti-TL1A antibody for inflammatory bowel disease.
Absci is publicly traded on NASDAQ (ABSI) and describes its approach as Integrated Drug Creation — combining computational design with laboratory execution to move from AI-generated antibody candidates into clinical development faster than traditional discovery timelines.
What the company does
Absci develops generative AI models that design de novo antibodies and biologics optimized for specific targets, then validates candidates through internal wet-lab and manufacturing workflows. Its proprietary pipeline includes ABS-101 for inflammatory bowel disease, ABS-201 targeting prolactin receptor biology for androgenetic alopecia and endometriosis programs, and additional assets disclosed at 2024 R&D Day and subsequent IR updates.
The May 2025 Phase 1 initiation of ABS-101 marked Absci’s transition to clinical-stage biotech — McClain stated the trial represents the first proof point of a pipeline wholly designed and optimized using AI. ABS-101 is formulated for quarterly subcutaneous dosing with engineering aimed at superior potency against monomeric and trimeric TL1A and reduced immunogenicity risk.
Partner programs include expanded Almirall dermatology collaboration announced August 7, 2025, following successful delivery of AI-designed functional antibody leads against a difficult-to-drug target in the initial collaboration phase.
Who it serves
Absci serves dual audiences: internal pipeline development targeting significant unmet needs such as IBD and androgenetic alopecia, and pharmaceutical partners licensing its Integrated Drug Creation platform for targets where traditional discovery approaches failed. Almirall, AMD, and other collaborators referenced in IR materials use Absci for de novo biologic design in dermatology and beyond — while Absci retains wholly owned programs advancing toward clinical proof-of-concept readouts.
Company background
McClain founded Absci in 2011 in Vancouver, Washington, building from protein display and synthetic biology capabilities into a data-first generative AI drug creation company. Absci completed its public listing and raised capital to fund internal pipeline advancement alongside partnered programs. Chief Medical Officer Ransi Somaratne, MD, joined from Vertex Pharmaceuticals to lead clinical execution as ABS-201 and endometriosis Phase 2 plans progressed in 2025–2026 IR communications.
Absci’s geographic distinction — Vancouver, Washington versus Vancouver, British Columbia — matters for Brel country indexing; this profile lists United States headquarters explicitly per verified corporate IR datelines.
Product and AI capabilities
Absci’s generative AI designs antibody sequences and developability properties in silico, iterating with high-throughput experimental validation that feeds back into model training — a closed loop McClain emphasizes when contrasting Absci from discovery-only AI software licensors. ABS-101 moved from AI design to Phase 1 dosing in approximately two years at a fraction of typical industry cost per 2026 business update commentary in IR materials.
Investors and partners should monitor interim safety, PK/PD, and proof-of-concept readouts — AI design speed matters only if clinical endpoints validate biological hypotheses.
Key developments
2011: Absci founded in Vancouver, Washington. May 13, 2025: First participants dosed in ABS-101 Phase 1 (investors.absci.com IR release). August 7, 2025: Almirall collaboration expanded with second dermatology target (IR release). December 12, 2024: R&D Day pipeline updates including ABS-201 and ABS-501 introduction.
Why it matters
Absci matters because generative AI drug creation requires clinical validation to prove economic value — ABS-101 Phase 1 dosing is Absci’s first major human proof point for AI-designed biologics. McClain’s pipeline strategy targets whitespace indications with limited approved disease-modifying therapies, where faster design-to-clinic timelines could justify AI-native biotech ownership versus licensing models alone. Absci complements Brel biotechnology coverage near other AI drug discovery companies but distinguishes itself through owned clinical-stage assets.
Sector context
Absci belongs in Brel’s AI in healthcare coverage under biotechnology and AI drug discovery, related to generative biology companies such as Generate Biomedicines. Readers should track IND status and trial readouts separately from partnership expansion press releases.
Sources and references
Absci ABS-101 Phase 1 dosing IR release (May 13, 2025) and Board of Directors page.
- Absci — ABS-101 Phase 1 initiation (investors.absci.com, May 13, 2025)
- Absci — Board of Directors (absci.com)
Reviewed July 10, 2026. Sean McClain is Founder and CEO. Headquarters Vancouver, Washington, United States.